Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2-specific ELISA development.
Roy V, Fischinger S, Atyeo C, Slein M, Loos C, Balazs A, Luedemann C, Astudillo MG, Yang D, Wesemann DR, Charles R, Lafrate AJ, Feldman J, Hauser B, Caradonna T, Miller TE, Murali MR, Baden L, Nilles E, Ryan E, Lauffenburger D, Beltran WG, Alter G. Roy V, et al. J Immunol Methods. 2020 Sep-Oct;484-485:112832. doi: 10.1016/j.jim.2020.112832. Epub 2020 Aug 8. J Immunol Methods. 2020. PMID: 32780998 Free PMC article.
Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice.
Brady JM, Phelps M, MacDonald SW, Lam EC, Nitido A, Parsons D, Boutros CL, Deal CE, Garcia-Beltran WF, Tanno S, Natarajan H, Ackerman ME, Vrbanac VD, Balazs AB. Brady JM, et al. Among authors: balazs ab. Sci Transl Med. 2022 Jul 27;14(655):eabn9662. doi: 10.1126/scitranslmed.abn9662. Epub 2022 Jul 27. Sci Transl Med. 2022. PMID: 35895834 Free PMC article.
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Casazza JP, Cale EM, Narpala S, Yamshchikov GV, Coates EE, Hendel CS, Novik L, Holman LA, Widge AT, Apte P, Gordon I, Gaudinski MR, Conan-Cibotti M, Lin BC, Nason MC, Trofymenko O, Telscher S, Plummer SH, Wycuff D, Adams WC, Pandey JP, McDermott A, Roederer M, Sukienik AN, O'Dell S, Gall JG, Flach B, Terry TL, Choe M, Shi W, Chen X, Kaltovich F, Saunders KO, Stein JA, Doria-Rose NA, Schwartz RM, Balazs AB, Baltimore D, Nabel GJ, Koup RA, Graham BS, Ledgerwood JE, Mascola JR; VRC 603 Study Team. Casazza JP, et al. Among authors: balazs ab. Nat Med. 2022 May;28(5):1022-1030. doi: 10.1038/s41591-022-01762-x. Epub 2022 Apr 11. Nat Med. 2022. PMID: 35411076 Free PMC article. Clinical Trial.
Delivery platforms for broadly neutralizing antibodies.
Joshi LR, Gálvez NMS, Ghosh S, Weiner DB, Balazs AB. Joshi LR, et al. Among authors: balazs ab. Curr Opin HIV AIDS. 2023 Jul 1;18(4):191-208. doi: 10.1097/COH.0000000000000803. Epub 2023 May 15. Curr Opin HIV AIDS. 2023. PMID: 37265268 Review.
Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge.
Welles HC, Jennewein MF, Mason RD, Narpala S, Wang L, Cheng C, Zhang Y, Todd JP, Lifson JD, Balazs AB, Alter G, McDermott AB, Mascola JR, Roederer M. Welles HC, et al. Among authors: balazs ab. PLoS Pathog. 2018 Dec 5;14(12):e1007395. doi: 10.1371/journal.ppat.1007395. eCollection 2018 Dec. PLoS Pathog. 2018. PMID: 30517201 Free PMC article.
103 results